The SUPERB Trial

Michel M.P.J. Reijnen

The SUPERB Trial

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The SUPERB trial is a multicenter randomized trial that was designed to prove the concept of endoluminal bypass with the heparin-bonded Gore Viabahn self-expanding endoprosthesis in comparison with the gold standard, the venous femoropopliteal bypass, based on the non-inferiority principle for primary patency. Besides equal patency, an improved quality of life is expected at 30 days. Recruitment was performed from November 2010 to June 2015 and patients will be followed over 5 years. Patients with an indication for surgical bypass, classified category 3-6 with a >50% stenosis or occlusion of the superficial femoral artery ≥10 cm in length, were included. At least one crural artery should be patent without significant lesions.

Original language	English
Pages (from-to)	E189-E191
Journal	Vascular Disease Management
Volume	14
Issue number	8
Publication status	Published - 1 Aug 2017
Externally published	Yes

Keywords

n/a OA procedure

Access to Document

https://www.vasculardiseasemanagement.com/content/superb-trial

Cite this

@article{ff0bc9a541224380a53296184f7acac2,

title = "The SUPERB Trial",

abstract = "The SUPERB trial is a multicenter randomized trial that was designed to prove the concept of endoluminal bypass with the heparin-bonded Gore Viabahn self-expanding endoprosthesis in comparison with the gold standard, the venous femoropopliteal bypass, based on the non-inferiority principle for primary patency. Besides equal patency, an improved quality of life is expected at 30 days. Recruitment was performed from November 2010 to June 2015 and patients will be followed over 5 years. Patients with an indication for surgical bypass, classified category 3-6 with a >50% stenosis or occlusion of the superficial femoral artery ≥10 cm in length, were included. At least one crural artery should be patent without significant lesions.",

keywords = "n/a OA procedure",

author = "Reijnen, {Michel M.P.J.}",

year = "2017",

month = aug,

day = "1",

language = "English",

volume = "14",

pages = "E189--E191",

journal = "Vascular Disease Management",

issn = "1553-8036",

publisher = "HMP Communications",

number = "8",

}

TY - JOUR

T1 - The SUPERB Trial

AU - Reijnen, Michel M.P.J.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The SUPERB trial is a multicenter randomized trial that was designed to prove the concept of endoluminal bypass with the heparin-bonded Gore Viabahn self-expanding endoprosthesis in comparison with the gold standard, the venous femoropopliteal bypass, based on the non-inferiority principle for primary patency. Besides equal patency, an improved quality of life is expected at 30 days. Recruitment was performed from November 2010 to June 2015 and patients will be followed over 5 years. Patients with an indication for surgical bypass, classified category 3-6 with a >50% stenosis or occlusion of the superficial femoral artery ≥10 cm in length, were included. At least one crural artery should be patent without significant lesions.

AB - The SUPERB trial is a multicenter randomized trial that was designed to prove the concept of endoluminal bypass with the heparin-bonded Gore Viabahn self-expanding endoprosthesis in comparison with the gold standard, the venous femoropopliteal bypass, based on the non-inferiority principle for primary patency. Besides equal patency, an improved quality of life is expected at 30 days. Recruitment was performed from November 2010 to June 2015 and patients will be followed over 5 years. Patients with an indication for surgical bypass, classified category 3-6 with a >50% stenosis or occlusion of the superficial femoral artery ≥10 cm in length, were included. At least one crural artery should be patent without significant lesions.

KW - n/a OA procedure

UR - http://www.scopus.com/inward/record.url?scp=85032737592&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85032737592

SN - 1553-8036

VL - 14

SP - E189-E191

JO - Vascular Disease Management

JF - Vascular Disease Management

IS - 8

ER -

The SUPERB Trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this